Clovis Oncology (CLVS) Prices 11.09M Share Common Offering at $8.05/Sh

After-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)

After-Hours Stock Movers:

Arbutus Biopharma Corporation (Nasdaq: ABUS) 55% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 14.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

Gamida Cell... More

Clovis Oncology (CLVS) Announces $85M Proposed Offering of Common Stock

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it has commenced an underwritten public offering of common stock.

Clovis Oncology intends to offer, subject to market and other conditions, $85 million of shares of its common stock in an underwritten registered public offering. In... More

Clovis Oncology (CLVS) PT Raised to $33 at H.C. Wainwright

H.C. Wainwright analyst Edward Wright raised the price target on Clovis Oncology (NASDAQ: CLVS) to $33.00 (from $29.00) while maintaining a Buy rating.

The analyst commented, "On Friday, Clovis announced that the FDA granted accelerated approval for Rubraca in patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer (mCRPC) patients who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The label was as we had expected with no surprises. Rubraca is Clovis oral,... More

Clovis Oncology (CLVS) Received FDA Approval for Rubraca as Monotherapy Treatment for Patients with BRCA1/2-Mutant, mCRPC

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The FDA approved this indication under accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the multi-center, single arm TRITON2 clinical trial. Continued approval for this indication may be contingent upon verification and description... More